

FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US

Mar 22, 2013

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/fda-approves-novartis-tobi-podhalertm-certain-cystic-fibrosis-patients-first-and-only-dry-powder-inhaled-antibacterial-us-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/fda-approves-novartis-tobi-podhalertm-certain-cystic-fibrosis-patients-first-and-only-dry-powder-inhaled-antibacterial-us-0>